Pappas Capital's Asia Innovation Ventures is a $200M fund targeting next generation technologies in Asia. The fund was more than two years in the making and is a way to tap into innovation in China, Hong Kong and Singapore.
Pappas Capital targets $200M at next generation of Asian innovation
Chimerix Receives FDA Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
DURHAM, N.C., June 04, 2021 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted TEMBEXA® (brincidofovir) tablets and oral suspension approval for the treatment of smallpox. TEMBEXA is approved for adult and pediatric patients, including neonates.
Pfizer Acquires Amplyx Pharmaceuticals
NEW YORK--April 28, 2021--Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.
Reneo Pharmaceuticals Announces Pricing of Initial Public Offering
SAN DIEGO, April 08, 2021 -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $93.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Reneo. The shares are expected to begin trading on the Nasdaq Global Market on April 9, 2021 under the symbol “RPHM.”
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
DURHAM, N.C. -- January 6, 2021 -- Ribometrix, Inc., today announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets.
Ribometrix is focused on leveraging its RNA structural expertise and analytical capabilities to make the vast landscape of RNA, which is involved in a wide variety of disease processes, accessible to small molecule therapeutics. Ribometrix’s platform uses multiple specialized technologies, including world-leading structural analytic capabilities, to identify 3D motifs in RNA molecules and then design small molecule candidates that bind to these motifs to produce a therapeutic effect.
BioAtla Announces Pricing of Initial Public Offering
SAN DIEGO, Dec. 15, 2020 -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial public offering of 10,500,000 shares of common stock at a public offering price of $18.00 per share. All of the shares of common stock are being offered by BioAtla. The shares of common stock are expected to begin trading on the Nasdaq Global Market on December 16, 2020 under the ticker symbol "BCAB." The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by BioAtla, are expected to be approximately $189.0 million. The offering is expected to close on December 18, 2020, subject to the satisfaction of customary closing conditions. In addition, BioAtla has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
4D Molecular Therapeutics Announces Upsized Pricing of Initial Public Offering
EMERYVILLE, Calif., Dec. 10, 2020 -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today the pricing of its initial public offering of 8,400,000 shares of its common stock at a public offering price of $23.00 per share. All of the shares are being offered by 4DMT. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by 4DMT, are expected to be $193.2 million. In connection with the offering, 4DMT has granted the underwriters a 30-day option to purchase up to 1,260,000 additional shares of common stock. The shares are expected to begin trading on the Nasdaq Global Select Market on December 11, 2020 under the ticker symbol “FDMT.” The offering is expected to close on December 15, 2020, subject to satisfaction of customary closing conditions.
Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth
SAN DIEGO, Dec. 9, 2020 -- Reneo Pharmaceuticals, Inc. today announced it raised $95 million in a Series B financing co-led by Novo Ventures and Abingworth and supported by existing investors New Enterprise Associates, RiverVest Venture Partners, Pappas Capital, and Lundbeckfonden Ventures, as well as new investors Rock Springs Capital, Aisling Capital, Amzak Health, and other investors. Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases.
Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 30, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the company’s Marketing Authorization Application (MAA) for its investigational medicine, maralixibat, for the treatment of patients with progressive familial intrahepatic cholestasis type 2 (PFIC2), also known as bile salt export pump (BSEP) deficiency, was accepted for review (validated) by the European Medicines Agency (EMA). The validation of the application by the EMA confirms all essential regulatory elements are included in the submission such that the EMA can begin its review.
VelosBio to be Acquired by Merck for $2.75 billion
RESEARCH TRIANGLE PARK, NC, Nov. 5, 2020 -- Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. ("VelosBio" or the "Company"), has entered into a definitive agreement to be acquired by a subsidiary of Merck (NYSE: MRK) for $2.75 billion in cash, subject to customary adjustments. The exit is amongst Pappas Capital's most successful in its 25-plus-year history.
